• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

针对哌拉西林-他唑巴坦耐药/泛β-内酰胺敏感肺炎克雷伯菌菌株，人源化哌拉西林-他唑巴坦暴露的不一致性

Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains.

作者信息

Stainton S M, Monogue M L, Nicolau D P

机构信息

Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.

Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA

出版信息

Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00491-17. Print 2017 Jul.

DOI:10.1128/AAC.00491-17
PMID:28607019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5487623/
Abstract

Recent findings have identified strains that are pan-β-lactam susceptible (PBL-S) but piperacillin-tazobactam resistant (TZP-R) We assessed the efficacy of a humanized exposure of piperacillin-tazobactam (TZP) against 12 TZP-R/PBL-S isolates in an immunocompromised murine lung infection model. Discordance between the resistance profile and the efficacy of human-simulated TZP exposures against this phenotypic profile was observed. Additional studies are required to define the clinical implications of these TZP-R/PBL-S strains.

摘要

最近的研究发现了对所有β-内酰胺类药物敏感（PBL-S）但对哌拉西林-他唑巴坦耐药（TZP-R）的菌株。我们在免疫受损的小鼠肺部感染模型中评估了人源化暴露的哌拉西林-他唑巴坦（TZP）对12株TZP-R/PBL-S分离株的疗效。观察到耐药谱与模拟人体TZP暴露对该表型谱的疗效之间存在不一致。需要进一步的研究来确定这些TZP-R/PBL-S菌株的临床意义。

相似文献

1
Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains.针对哌拉西林-他唑巴坦耐药/泛β-内酰胺敏感肺炎克雷伯菌菌株，人源化哌拉西林-他唑巴坦暴露的不一致性
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00491-17. Print 2017 Jul.
2
In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.人源化哌拉西林-他唑巴坦暴露量与哌拉西林-他唑巴坦耐药/泛β-内酰胺敏感大肠埃希菌的体外-体内不一致性
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7527-7529. doi: 10.1128/AAC.01208-16. Print 2016 Dec.
3
SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible .产 SHV 超广谱β-内酰胺酶作为一种机制导致哌拉西林-他唑巴坦在对头孢菌素类药物敏感的.
Microb Drug Resist. 2020 Apr;26(4):334-340. doi: 10.1089/mdr.2019.0079. Epub 2019 Oct 25.
4
Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.哌拉西林-他唑巴坦耐药/第三代头孢菌素敏感的大肠埃希菌和肺炎克雷伯菌分离株：耐药机制和体外-体内不相符。
Int J Antimicrob Agents. 2020 Mar;55(3):105885. doi: 10.1016/j.ijantimicag.2020.105885. Epub 2020 Jan 8.
5
In vitro susceptibility of multi-drug resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolated from clinical specimens at Bugando Medical Centre, Tanzania to Piperacillin-Tazobactam.从坦桑尼亚布甘多医疗中心临床标本中分离出的耐多药铜绿假单胞菌和产超广谱β-内酰胺酶肺炎克雷伯菌对哌拉西林-他唑巴坦的体外敏感性
Tanzan J Health Res. 2014 Jan;16(1):54-7. doi: 10.4314/thrb.v16i1.8.
6
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.肠外β-内酰胺类药物对产超广谱β-内酰胺酶和不产ESBL的肺炎克雷伯菌标准接种量和高接种量的体外杀菌作用
Diagn Microbiol Infect Dis. 2004 May;49(1):41-6. doi: 10.1016/j.diagmicrobio.2003.11.007.
7
Conjugative resistance to tazobactam plus piperacillin among extended-spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae.产超广谱β-内酰胺酶的医院内肺炎克雷伯菌对他唑巴坦加哌拉西林的接合耐药性
Scand J Infect Dis. 2001;33(7):512-5. doi: 10.1080/00365540110026520.
8
Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.希腊一家三级护理医院实施限制政策后，肺炎克雷伯菌和大肠埃希菌临床分离株对第三代和第四代头孢菌素以及哌拉西林/他唑巴坦耐药模式变化的差异。
Int J Antimicrob Agents. 2007 Jan;29(1):34-8. doi: 10.1016/j.ijantimicag.2006.08.042.
9
The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.哌拉西林/他唑巴坦的广泛使用对侵袭性大肠埃希菌和肺炎克雷伯菌分离株抗生素耐药性选择的影响。
Int J Infect Dis. 2013 Aug;17(8):e638-43. doi: 10.1016/j.ijid.2013.01.030. Epub 2013 Mar 21.
10
In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.产超广谱β-内酰胺酶肺炎克雷伯菌不同接种量时哌拉西林-他唑巴坦和美罗培南的体外和体内活性。
Clin Microbiol Infect. 2014 Nov;20(11):O831-9. doi: 10.1111/1469-0691.12677. Epub 2014 Jun 14.

引用本文的文献

1
Piperacillin/tazobactam-resistant, cephalosporin-susceptible bloodstream infections are driven by multiple acquisition of resistance across diverse sequence types.对哌拉西林/他唑巴坦耐药、头孢菌素敏感的血流感染是由多种不同序列型的耐药性获得驱动的。
Microb Genom. 2022 Apr;8(4). doi: 10.1099/mgen.0.000789.
2
Epidemiology of Bloodstream Infections Caused by and That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible.由对哌拉西林 - 他唑巴坦不敏感但对头孢曲松敏感的[细菌名称未给出]引起的血流感染的流行病学
Open Forum Infect Dis. 2018 Nov 19;5(12):ofy300. doi: 10.1093/ofid/ofy300. eCollection 2018 Dec.
3
Assessment of the Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.评估 WCK 5222（头孢吡肟-齐他培南）在中性粒细胞减少症小鼠肺部感染模型中对碳青霉烯类耐药鲍曼不动杆菌的疗效。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.00948-18. Print 2018 Nov.
4
Assessment of the Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model.评估 SPR741 联合阿奇霉素对中性粒细胞减少症小鼠大腿感染模型中多药耐药肠杆菌科分离株的活性。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00239-18. Print 2018 Jul.
5
Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.广泛基因扩增作为大肠埃希菌对哌拉西林-他唑巴坦耐药的机制。
mBio. 2018 Apr 24;9(2):e00583-18. doi: 10.1128/mBio.00583-18.

本文引用的文献

1
In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.人源化哌拉西林-他唑巴坦暴露量与哌拉西林-他唑巴坦耐药/泛β-内酰胺敏感大肠埃希菌的体外-体内不一致性
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7527-7529. doi: 10.1128/AAC.01208-16. Print 2016 Dec.
2
Impact of blaNDM-1 on fitness and pathogenicity of Escherichia coli and Klebsiella pneumoniae.blaNDM-1 对大肠杆菌和肺炎克雷伯菌的适应性和致病性的影响。
Int J Antimicrob Agents. 2016 Jun;47(6):430-5. doi: 10.1016/j.ijantimicag.2016.02.019. Epub 2016 Apr 26.
3
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.头孢洛扎/他唑巴坦及其他胃肠外抗菌药物对美国医院分离的大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌的药敏谱
Clin Ther. 2015 Jul 1;37(7):1564-71. doi: 10.1016/j.clinthera.2015.05.501. Epub 2015 Jun 15.
4
Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.抗菌药物耐药性：对临床和经济结果的影响以及对新型抗菌药物的需求。
Expert Opin Pharmacother. 2015 Feb;16(2):159-77. doi: 10.1517/14656566.2015.993381. Epub 2014 Dec 13.
5
Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.在中空纤维药效学模型中头孢他啶和阿维巴坦对产β-内酰胺酶肠杆菌科细菌的活性
Antimicrob Agents Chemother. 2014 Jun;58(6):3366-72. doi: 10.1128/AAC.00080-14. Epub 2014 Mar 31.
6
Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.头孢他啶和头孢他啶-阿维巴坦人体模拟剂量对铜绿假单胞菌的体外和体内疗效比较。
Antimicrob Agents Chemother. 2012 Dec;56(12):6137-46. doi: 10.1128/AAC.00851-12. Epub 2012 Sep 17.
7
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.在体内比较 CXA-101（FR264205）与他唑巴坦联用和不联用哌拉西林-他唑巴坦对表型多样的革兰氏阴性菌的模拟人体暴露效果。
Antimicrob Agents Chemother. 2012 Jan;56(1):544-9. doi: 10.1128/AAC.01752-10. Epub 2011 Nov 7.
8
Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.产碳青霉烯酶肺炎克雷伯菌的双重碳青霉烯类治疗。
Antimicrob Agents Chemother. 2011 Jun;55(6):3002-4. doi: 10.1128/AAC.01420-10. Epub 2011 Mar 21.
9
In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.模拟人体延长输注美罗培南给药方案对产碳青霉烯酶肺炎克雷伯菌的体内疗效。
Antimicrob Agents Chemother. 2010 Oct;54(10):4112-5. doi: 10.1128/AAC.00026-10. Epub 2010 Jul 26.
10
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.高产率、长时间人模拟输注美罗培南对产 KPC 碳青霉烯酶肺炎克雷伯菌与体外药效动力学模型中铜绿假单胞菌的活性比较。
Antimicrob Agents Chemother. 2010 Feb;54(2):804-10. doi: 10.1128/AAC.01190-09. Epub 2009 Dec 7.